Sirtris, Helicos file IPOs

Sirtris Pharmaceuticals has filed a $60 million IPO with the SEC. Sirtris is testing a "resveratrol-based" drug against diabetes. Resveratrol recently gained attention when several studies suggested that the compound, which is found in red wine, can be used to counter the ailments associated with age and obesity. The number of shares to be offered and the price range for the offering have not yet been determined.

- check out Sirtris' press release

PLUS: Helicos BioSciences has filed a $100 million IPO. Helicos is developing genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Release

ALSO: Canada's OncoGenex has cut its planned initial public offering to $7.50 to $8.50 per share from a previous range of $10 to $12. Release

Related Articles:
Ingredient in wine may boost longevity, health. Report
Sirtris pockets $37M in venture funds. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.